Weight maintenance after stopping GLP-1 treatments depends on factors like diet, exercise, and lifestyle habits
Doubling up can significantly increase the risk of severe gastrointestinal side effects like nausea and vomiting
Licensed-provider evaluation, the compounded semaglutide medication dispensed by a US-licensed compounding pharmacy, ongoing telehealth support, and free discreet shipping
Many GLP-1 side effects improve with dose adjustment, medication timing changes, or dietary modifications
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
Sustained Levels Supplemental glutathione can provide a more immediate increase in cellular levels, especially when delivered via a liposomal format
